New diagnostics tool, the Xpert Ultra assay, improves detection of mycobacterium tuberculosis

August 29, 2017, American Society for Microbiology

Researchers have demonstrated a new, improved version of the Xpert MTB/RIF assay, a test for Rifampicin-resistance (RIF-R). The Xpert "Ultra" assay overcomes the shortcomings of the current Xpert assay to significantly improve tuberculosis detection, especially in patients with pauci-bacillary disease. The new Xpert Ultra assay also provides a more reliable detection of Rifampicin resistance (RIF-R). The research is published this week in mBio, an open-access journal of the American Society for Microbiology.

The Xpert MTB/RIF (Xpert) assay, the first point-of-care assay for tuberculosis (TB), was endorsed by World Health Organization in December 2010. Although it shows high overall sensitivity and specificity, it has several limitations, such as yielding both false positive and false negative results for the prediction of RIF-R in pauci-bacillary samples. This study shows that the new Ultra assay format, which includes new gene target amplifications and improves previously amplified targets, overcomes many of the known shortcomings of the Xpert assay, and should significantly improve TB detection.

Explore further: Automated Ebola blood test performs well in field evaluation

Related Stories

Automated Ebola blood test performs well in field evaluation

March 29, 2016
An automated "sample-to-answer" system could provide Ebola virus disease (EVD) diagnosis more quickly and easily than the current standard test, according to research published this week in PLOS Medicine. In a field evaluation ...

Assay for pulmonary tuberculosis and rifa mpicin resistance in adults

January 22, 2014
A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated review assessing the accuracy of Xpert® MTB/RIF includes ...

FDA approves new test to help detect drug-resistant bacteria

July 1, 2016
(HealthDay)—The Xpert Carba-R Assay diagnostic, which tests patient specimens for genetic markers associated with drug-resistant bacteria, has been approved by the U.S. Food and Drug Administration.

New TB drug-resistance test shows promise but needs investment for those diagnosed to be cured

July 26, 2011
Two research studies in this week's PLoS Medicine suggest that a new automated DNA test for tuberculosis (Xpert MTB/RIF), which can detect TB within 2 hours and has been endorsed by the World Health Organization, can significantly ...

XPert MTB/RIF cost effective for TB diagnosis in low- and middle-income settings

November 8, 2011
A study led by Frank Cobelens of the Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands and colleagues reports on the cost-effectiveness of implementing the Xpert MTB/RIF diagnostic test for ...

Tuberculosis: WHO-endorsed test offers rapid detection

January 30, 2013
A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® ...

Recommended for you

Research shows possible new target for immunotherapy for solid tumors

April 24, 2018
Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

Scientists develop a new model for glioblastoma using gene-edited organoids

April 24, 2018
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't ...

Removing the enablers: Reducing number of tumor-supporting cells to fight neuroblastoma

April 24, 2018
Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles provide preclinical evidence that the presence of tumor-associated macrophages—a type of immune cell—can negatively ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.